



China Blood Product Industry Report, 2016-2019

Mar. 2016

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.


Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China's production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China's total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises --- Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products -- human immunoglobulin (ph4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxing had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da'an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.



China Blood Product Industry Report, 2016-2019 focuses on the followings:

- Market characteristics, operating environments, status quo, etc. of China blood product industry;
- Supply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;
- Supply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;
- Operation, blood product business and prospects of 13 major Chinese blood product companies.

Copyright 2012ResearchInChina

1. Overview of Blood Product Industry

- 1.1 Definition
- 1.2 Classification
- 1.3 Recombinant Blood Products
- 1.4 Industry Chain
- 1.5 Features

2. Overview of China Blood Product Industry

- 2.1 Market Size
- 2.2 Status Quo
- 2.3 Supply and Demand
 - 2.3.1 Supply
 - 2.3.2 Demand
- 2.4 Competition
- 2.5 Operating Environment
 - 2.5.1 International
 - 2.5.2 Policy
 - 2.5.3 Domestic Biopharmaceutical Market
- 2.6 Import and Export

3. Blood Product Market Segments in China

- 3.1 Human Albumin
 - 3.1.1 Supply and Demand
 - 3.1.2 Competition Pattern
 - 3.1.3 Prospects
- 3.2 Human Immunoglobulin (pH4) for Intravenous Injection

- 3.2.1 Supply and Demand

- 3.2.2 Competition Pattern

- 3.3 Blood Coagulation Factor VIII

- 3.3.1 Supply and Demand

- 3.3.2 Competition Pattern

- 3.3.3 Prospects

- 3.4 Hepatitis B Immunoglobulin

- 3.4.1 Supply and Demand

- 3.4.2 Competition Pattern

- 3.5 Human Immunoglobulin

- 3.5.1 Supply and Demand

- 3.5.2 Competition Pattern

- 3.6 Human Prothrombin Complex

- 3.6.1 Supply and Demand

- 3.6.2 Competition Pattern

- 3.7 Tetanus Immunoglobulin

- 3.7.1 Supply and Demand

- 3.7.2 Competition Pattern

- 3.8 Human Rabies Immunoglobulin

- 3.8.1 Supply and Demand

- 3.8.2 Competition Pattern

4. Major Chinese Manufacturers

- 4.1 China Biologic Products Inc. (NASDAQ: CBPO)

- 4.1.1 Profile

- 4.1.2 Operation

- 4.1.3 Revenue Structure

- 4.1.4 Customers and Suppliers

- 4.1.5 R&D and Investment

- 4.1.6 Shandong Taibang Biological Products Co., Ltd.

- 4.1.7 Guizhou Taibang Biological Products Co., Ltd.

- 4.1.8 Xi'an Huitian Blood Products Co., Ltd.

- 4.1.9 Outlook and Prospects

- 4.2 Hualan Biological Engineering Inc. (002007.SZ)

- 4.2.1 Profile

- 4.2.2 Operation

- 4.2.3 Revenue Structure

- 4.2.4 Gross Margin

- 4.2.5 Customers and Suppliers

- 4.2.6 R&D and Investment

- 4.2.7 Blood Products

- 4.2.8 Outlook and Prospects

- 4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)

- 4.3.1 Profile

- 4.3.2 Operation

- 4.3.3 Revenue Structure

- 4.3.4 Gross Margin

- 4.3.5 Customers and Suppliers

- 4.3.6 R&D and Investment

- 4.3.7 Outlook and Prospects

- 4.4 Beijing Tiantan Biological Products Co., Ltd. (TIAN TAN BIO, 600161.SH)

- 4.4.1 Profile

4.4.2 Operation	4.6.7 Outlook and Prospects
4.4.3 Revenue Structure	4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.4.4 Customers and Suppliers	4.7.1 Profile
4.4.5 Gross Margin	4.7.2 Blood Products
4.4.6 R&D and Investment	4.8 Shanghai Institute of Biological Products Co., Ltd.
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)	4.8.1 Profile
4.4.8 Outlook and Prospects	4.8.2 Blood Products
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)	4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.5.1 Profile	4.9.1 Profile
4.5.2 Operation	4.9.2 Blood Products
4.5.3 Revenue Structure	4.10 Green Cross
4.5.4 Gross Margin	4.10.1 Profile
4.5.5 Customers and Suppliers	4.10.2 Blood Products
4.5.6 R&D and Investment	4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)	4.11.1 Profile
4.5.8 Outlook and Prospects	4.11.2 Operation
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)	4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.6.1 Profile	4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.6.2 Operation	4.12.1 Profile
4.6.3 Revenue Structure	4.12.2 Operation
4.6.4 Gross Margin	4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
4.6.5 Customers and Suppliers	4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.6.6 R&D and Investments	
	5. Summary and Forecast
	5.1 Company Analysis
	5.2 Growth Prediction


Selected Charts

- Basic Components of Blood
- Plasma Protein Separation Procedure
- Classification and Function of Blood Products
- Comparison between Gene Recombinant Blood Products and Traditional Blood Products
- Comparison between Domestic and Foreign Recombinant Blood Products in Types
- Blood Product Industry Chain
- Time Consumption of Plasma Collection and Separation Process
- Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
- Prices of Some Blood Products in China, 2014
- Blood Product Market Size in China, 2003-2015
- Lot Release Volume of Blood Products in China (by Product), 2009-2015
- Blood Product Structure in China (by Lot Release Volume), 2009-2015
- Per Capita Frequency of Plasma Donation and Plasma Collection in China vs. the Occident
- Plasma Collections in China vs. USA
- Production-use Plasma Volume in China, 2008-2015
- Number of Plasma Collection Stations in China, 2008-2015
- Geographical Distribution of Plasma Station Resources in China by the End of 2015
- Mainstream Blood Products with Medical Insurance Coverage in China
- Per Capita Consumption of Blood Products in China vs. Developed Countries
- Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2014
- Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2015
- Comparison of Chinese Blood Product Manufacturing Enterprises in Product Line
- Competition Pattern of Global Blood Product Enterprises, 2013

- 
- Product Structure of Global Blood Products
 - Blood Products Available in Overseas Market
 - Global Blood Product Manufacturers
 - Main Policies on Chinese Blood Products
 - Policies on Maximum Retail Price of Drugs in China, 2014-2015
 - Lot Release Volume of Imported Human Albumin in China, 2008-2015
 - Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
 - Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2015
 - Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2015
 - Consumption of Human Immunoglobulin (pH4) for Intravenous Injection per 1,000 Persons by Country, 2013 (g/1,000 persons)
 - Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2015
 - Price of Human Immunoglobulin (pH4) for Intravenous Injection in China vs. Other Countries
 - Average Purchase Price of Human Immunoglobulin (pH4) for Intravenous Injection of Sample Hospitals in China, 2005-2014
 - Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2015
 - Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2015
 - Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2015
 - Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
 - Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries (IU/Person)
 - Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2015
 - Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
 - Prices of Human Immunoglobulin in China by Dosage, 2014
 - Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2015
 - Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
 - Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2015

Selected Charts

- Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2015
- Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2015
- Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
- Rabies Incidents and Death Rate in China, 2008-2014
- Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2015
- Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
- Equity Structure of China Biologic Products by the End of 2014
- Distribution of Blood Products Manufacturing Bases and Plasma Stations of CBPO, 2015
- Revenue and Operating Income of CBPO, 2008-2015
- Gross Margin of CBPO, 2011-2015
- Revenue Breakdown of CBPO (by Product), 2011-2015
- Revenue Structure of CBPO (by Product), 2010-2015
- CBPO's Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
- R&D Costs and % of Total Revenue of CBPO, 2010-2015
- Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2008-2015
- Lot Release Volume of Blood Products of Guiyang Qianfeng Biological Products, 2008-2015
- Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
- Revenue and Operating Income of CBPO, 2014-2019E
- Revenue and Operating Income of Hualan Biological Engineering Inc., 2008-2015
- Revenue of Hualan Biological Engineering Inc. (by Sector), 2008-2015
- Gross Margin of Hualan Biological Engineering Inc. (by Product), 2008-2015
- Hualan Biological Engineering Inc.'s Revenue from Top 5 Customers and % of Total Revenue, 2007-2014
- Hualan Biological Engineering Inc.'s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
- Name List and Procurement Contribution of Hualan Biological Engineering Inc.'s Top 5 Suppliers, 2014
- R&D Costs and % of Total Revenue of Hualan Biological Engineering Inc., 2008-2015

- 
- Types and Specifications of Blood Products of Hualan Biological Engineering Inc.
 - Distribution of Plasma Collection Stations of Hualan Biological Engineering Inc. by the End of 2015
 - Lot Release Volume of Blood Products of Hualan Biological Engineering Inc., 2008-2015
 - Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc., 2008-2015
 - Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc. (by Product), 2008-2015
 - Revenue and Operating Income of Hualan Biological Engineering Inc., 2014-2019E
 - Shanghai RAAS's Subsidiaries and Their Operation, H1 2015 (RMB mln)
 - Distribution of Plasma Stations of Shanghai RAAS by the End of 2015
 - Revenue and Operating Income of Shanghai RAAS, 2008-2015
 - Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2015
 - Lot Release Volume of Blood Products of Tonrol Bio-Pharmaceutical, 2008-2015
 - Operating Revenue of Shanghai RAAS (by Product), 2008-2015
 - Revenue of Shanghai RAAS (by Region), 2008-2015
 - Gross Margin of Shanghai RAAS (by Product), 2008-2015
 - Shanghai RAAS's Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
 - Shanghai RAAS's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
 - R&D Costs and % of Total Revenue of Shanghai RAAS, 2008-2015
 - Revenue and Operating Income of Shanghai RAAS, 2014-2019E
 - Tiantanbio's Subsidiaries and Their Revenue and Income, H1 2015 (RMB mln)
 - Revenue and Operating Income of Tiantanbio, 2008-2015
 - Revenue of Tiantanbio (by Sector), 2008-2015
 - Revenue of Tiantanbio (by Region), 2008-2015
 - Tiantanbio's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2014
 - Tiantanbio's Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
 - Gross Margin of Tiantanbio (by Sector), 2008-2015

- R&D Costs and % of Total Revenue of Tiantanbio, 2009-2015
- Distribution of Plasma Collection Stations of Tiantanbio by the End of 2015
- Revenue and Gross Margin of Blood Products of Tiantanbio, 2008-2015
- Lot Release Volume of Blood Products of RonSen and Tiantanbio, 2008-2015
- Revenue and Operating Income of Tiantanbio, 2014-2019E
- Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2015
- Operating Revenue of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
- Gross Margin of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2013
- Zhenxing Biopharmaceutical and Chemical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2014
- Name List and Revenue Contribution of Zhenxing Biopharmaceutical and Chemical's Top 5 Customers, 2014
- Zhenxing Biopharmaceutical and Chemical's Procurement from Top 5 Suppliers and % of Total Procurement, 2014
- R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2015
- Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2015
- Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2015
- Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2015
- Revenue and Gross Margin of Blood Products of Zhenxing Biopharmaceutical and Chemical, 2009-2015
- Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2019E
- Distribution of Single Plasma Collection Stations of Jiangxi Boya Bio-Pharmaceutical by the End of 2015
- Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
- Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
- Revenue of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
- Lot Release Volume of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
- Operating Revenue of Jiangxi Boya Bio-Pharmaceutical (by Region), 2009-2014
- Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
- Jiangxi Boya Bio-Pharmaceutical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2015

Selected Charts

- Jiangxi Boya Bio-Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2015
- R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2015
- Products under Research and Progress of Jiangxi Boya Bio-Pharmaceutical as of Oct. 2015
- Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2019E
- Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical by the End of 2015
- Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2015
- Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2008-2015
- Distribution of Plasma Stations of Shanghai Institute of Biological Products by the End of 2015
- Distribution of Plasma Stations of Shanxi Kangbao Biological Product by the End of 2015
- Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2015
- Distribution of Plasma Stations of Green Cross China by the End of 2015
- Lot Release Volume of Blood Products of Green Cross China, 2008-2015
- Revenue and Operating Income of Humanwell Healthcare, 2009-2015
- Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2015
- Production Industry Layout of Walvax Biotechnology
- Revenue and Operating Income of Walvax Biotechnology, 2009-2015
- Revenue of Walvax Biotechnology (by Product), 2009-2015
- Distribution of Single Plasma Collection Stations of Shenzhen Weiguang Biological Products by the End of 2015
- Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
- Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
- Capacity, Production and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
- Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
- Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
- Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
- Name List and Revenue Contribution of Shenzhen Weiguang Biological Products' Top 5 Customers, 2012-2015

Selected Charts

- 
- Name List and Procurement Contribution of Shenzhen Weiguang Biological Products' Top 5 Suppliers, 2012-2015
 - R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
 - Some Products under Research and Progress of Shenzhen Weiguang Biological Products by the End of 2015
 - Fundraising Projects of Shenzhen Weiguang Biological Products
 - Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2014-2019E
 - Number of Plasma Stations of Major Blood Product Enterprises in China as of Dec. 2015
 - Production-use Plasma Volume of Major Blood Product Enterprises in China, 2014-2015
 - Blood Product Revenue of Major Blood Product Enterprises in China, 2011-2015
 - Major M&A Events of Blood Product Industry in China, 2008-2015
 - Market Size of Blood Products in China, 2014-2019E
 - Gross Margin of Major Blood Product Enterprises in China, 2011-2015

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82601561

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
Total		

Choose type of format

PDF (Single user license)2,650 USD
 Hard copy 2,800 USD
 PDF (Enterprisewide license)..... 4,000 USD

※ Reports will be dispatched immediately once full payment has been received.
 Payment may be made by wire transfer or credit card via PayPal.

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- ❑ *Multi-users market reports*
- ❑ *Database-RICDB*
- ❑ *Custom Research*
- ❑ *Company Search*

For any problems, please contact our service team at: